Published in Blood on August 21, 2003
The development of immunoconjugates for targeted cancer therapy. Nat Rev Clin Oncol (2014) 1.49
Tumor-targeted TNFα stabilizes tumor vessels and enhances active immunotherapy. Proc Natl Acad Sci U S A (2012) 1.30
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther (2009) 1.12
TNF-alpha is critical for ischemia-induced leukostasis, but not retinal neovascularization nor VEGF-induced leakage. J Neuroimmunol (2006) 1.04
Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol (2013) 1.01
Fibronectin extra domain A (EDA) sustains CD133(+)/CD44(+) subpopulation of colorectal cancer cells. Stem Cell Res (2013) 1.00
Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther (2007) 0.99
Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes. Front Oncol (2013) 0.95
A chemically modified antibody mediates complete eradication of tumours by selective disruption of tumour blood vessels. Br J Cancer (2011) 0.94
Nanoparticle delivered vascular disrupting agents (VDAs): use of TNF-alpha conjugated gold nanoparticles for multimodal cancer therapy. Mol Pharm (2013) 0.91
Generation and characterization of monospecific and bispecific hexavalent trimerbodies. MAbs (2012) 0.91
Paradoxical roles of tumour necrosis factor-alpha in prostate cancer biology. Prostate Cancer (2012) 0.90
Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer (2010) 0.89
Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. MAbs (2012) 0.88
Phase I/II study of the tumour-targeting human monoclonal antibody-cytokine fusion protein L19-TNF in patients with advanced solid tumours. J Cancer Res Clin Oncol (2012) 0.88
Human monoclonal antibodies targeting carbonic anhydrase IX for the molecular imaging of hypoxic regions in solid tumours. Br J Cancer (2009) 0.87
A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol (2010) 0.85
Alternative splicing of the angiogenesis associated extra-domain B of fibronectin regulates the accessibility of the B-C loop of the type III repeat 8. PLoS One (2010) 0.84
The antibody-based targeted delivery of TNF in combination with doxorubicin eradicates sarcomas in mice and confers protective immunity. Br J Cancer (2013) 0.84
Molecular targeting of angiogenesis for imaging and therapy. Eur J Nucl Med Mol Imaging (2004) 0.82
Immunocytokines and bispecific antibodies: two complementary strategies for the selective activation of immune cells at the tumor site. Immunol Rev (2016) 0.82
Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines. J Transl Med (2012) 0.81
The isoflavone metabolite 6-methoxyequol inhibits angiogenesis and suppresses tumor growth. Mol Cancer (2012) 0.80
Use of uteroglobin for the engineering of polyvalent, polyspecific fusion proteins. J Biol Chem (2009) 0.80
Immunocytokines: a novel class of products for the treatment of chronic inflammation and autoimmune conditions. Drug Discov Today (2015) 0.79
Targeted Cancer Therapy with Tumor Necrosis Factor-Alpha. Biochem Insights (2008) 0.79
Mesenchymal stem cells modified to express lentivirus TNF-α Tumstatin(45-132) inhibit the growth of prostate cancer. J Cell Mol Med (2011) 0.79
Heptameric targeting ligands against EGFR and HER2 with high stability and avidity. PLoS One (2012) 0.79
Comparative analysis of oncofetal fibronectin and tenascin-C expression in right atrial auricular and left ventricular human cardiac tissue from patients with coronary artery disease and aortic valve stenosis. Histochem Cell Biol (2011) 0.78
Antibody-cytokine fusion proteins for treatment of cancer: engineering cytokines for improved efficacy and safety. Semin Oncol (2014) 0.77
Innovative proteomics for the discovery of systemically accessible cancer biomarkers suitable for imaging and targeted therapies. Am J Pathol (2010) 0.76
Novel ubiquitin-derived high affinity binding proteins with tumor targeting properties. J Biol Chem (2014) 0.76
Schedule-dependent therapeutic efficacy of L19mTNF-α and melphalan combined with gemcitabine. Cancer Med (2013) 0.76
Stromal Modulators of TGF-β in Cancer. J Clin Med (2017) 0.76
Beyond peptides and mAbs--current status and future perspectives for biotherapeutics with novel constructs. J Clin Pharmacol (2015) 0.76
Targeted Reconstitution of Cytokine Activity upon Antigen Binding using Split Cytokine Antibody Fusion Proteins. J Biol Chem (2016) 0.75
Evaluation of F8-TNF-α in Models of Early and Progressive Metastatic Osteosarcoma. Transl Oncol (2017) 0.75
Use of the uteroglobin platform for the expression of a bivalent antibody against oncofetal fibronectin in Escherichia coli. PLoS One (2013) 0.75
[Clinical and immunohistochemical findings of intra- and extraoral angiosarcomas]. Mund Kiefer Gesichtschir (2006) 0.75
Sarcoma eradication by doxorubicin and targeted TNF relies upon CD8+ T cell recognition of a retroviral antigen. Cancer Res (2017) 0.75
Blue silver: a very sensitive colloidal Coomassie G-250 staining for proteome analysis. Electrophoresis (2004) 6.97
Identification of PVR (CD155) and Nectin-2 (CD112) as cell surface ligands for the human DNAM-1 (CD226) activating molecule. J Exp Med (2003) 3.52
Identification of 4Ig-B7-H3 as a neuroblastoma-associated molecule that exerts a protective role from an NK cell-mediated lysis. Proc Natl Acad Sci U S A (2004) 1.95
Enhancement of the antitumor properties of interleukin-2 by its targeted delivery to the tumor blood vessel extracellular matrix. Blood (2002) 1.66
A combined method for producing homogeneous glycoproteins with eukaryotic N-glycosylation. Nat Chem Biol (2010) 1.66
Radioimmunotherapy of head and neck cancer xenografts using 131I-labeled antibody L19-SIP for selective targeting of tumor vasculature. J Nucl Med (2006) 1.62
Selective targeting of tumoral vasculature: comparison of different formats of an antibody (L19) to the ED-B domain of fibronectin. Int J Cancer (2002) 1.53
The immunocytokine L19-IL2 eradicates cancer when used in combination with CTLA-4 blockade or with L19-TNF. J Invest Dermatol (2012) 1.46
Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.45
Elevated expression of PDGF-C in coxsackievirus B3-induced chronic myocarditis. Eur Heart J (2005) 1.45
Periostin promotes fibrosis and predicts progression in patients with idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol (2012) 1.44
Fibronectin as target for tumor therapy. Int J Cancer (2006) 1.44
Cherubism - new hypotheses on pathogenesis and therapeutic consequences. J Craniomaxillofac Surg (2005) 1.43
Complete eradication of human B-cell lymphoma xenografts using rituximab in combination with the immunocytokine L19-IL2. Blood (2008) 1.42
Design, construction, and characterization of a large synthetic human antibody phage display library. Proteomics (2005) 1.42
Encoded self-assembling chemical libraries. Nat Biotechnol (2004) 1.40
A high-affinity human monoclonal antibody specific to the alternatively spliced EDA domain of fibronectin efficiently targets tumor neo-vasculature in vivo. Int J Cancer (2008) 1.36
In vivo protein biotinylation for identification of organ-specific antigens accessible from the vasculature. Nat Methods (2005) 1.32
Immunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin Cancer Res (2003) 1.31
E-3810 is a potent dual inhibitor of VEGFR and FGFR that exerts antitumor activity in multiple preclinical models. Cancer Res (2011) 1.28
Antibody-radionuclide conjugates for cancer therapy: historical considerations and new trends. Clin Cancer Res (2011) 1.27
The extra-domain A of fibronectin is a vascular marker of solid tumors and metastases. Cancer Res (2007) 1.26
Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res (2006) 1.23
Immunocytokines: a novel class of potent armed antibodies. Drug Discov Today (2012) 1.20
High-throughput sequencing allows the identification of binding molecules isolated from DNA-encoded chemical libraries. Proc Natl Acad Sci U S A (2008) 1.18
Antibody-drug conjugates: basic concepts, examples and future perspectives. J Control Release (2012) 1.18
TLE1 is a robust diagnostic biomarker for synovial sarcomas and correlates with t(X;18): analysis of 319 cases. Eur J Cancer (2010) 1.16
The antibody-mediated targeted delivery of interleukin-15 and GM-CSF to the tumor neovasculature inhibits tumor growth and metastasis. Cancer Res (2007) 1.14
Modulation of gene expression by hypoxia in human umbilical cord vein endothelial cells: A transcriptomic and proteomic study. Proteomics (2004) 1.14
Near-infrared fluorescence imaging of HER-2 protein over-expression in tumour cells. Eur Radiol (2004) 1.12
Preclinical characterization of DEKAVIL (F8-IL10), a novel clinical-stage immunocytokine which inhibits the progression of collagen-induced arthritis. Arthritis Res Ther (2009) 1.12
Differentiation between high- and low-grade astrocytoma using a human recombinant antibody to the extra domain-B of fibronectin. Am J Pathol (2002) 1.12
PVR (CD155) and Nectin-2 (CD112) as ligands of the human DNAM-1 (CD226) activating receptor: involvement in tumor cell lysis. Mol Immunol (2005) 1.11
In vivo imaging of inflammation- and tumor-induced lymph node lymphangiogenesis by immuno-positron emission tomography. Cancer Res (2010) 1.10
Isolation of high-affinity trypsin inhibitors from a DNA-encoded chemical library. Angew Chem Int Ed Engl (2007) 1.10
Oral acantholytic squamous cell carcinoma shares clinical and histological features with angiosarcoma. Head Face Med (2008) 1.08
DAMPs and inflammatory processes: the role of redox in the different outcomes. J Leukoc Biol (2009) 1.08
Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta (2007) 1.08
Purification of biotinylated proteins on streptavidin resin: a protocol for quantitative elution. Proteomics (2004) 1.08
The redox state of the lung cancer microenvironment depends on the levels of thioredoxin expressed by tumor cells and affects tumor progression and response to prooxidants. Int J Cancer (2008) 1.07
Engineered vascular-targeting antibody-interferon-gamma fusion protein for cancer therapy. Int J Cancer (2005) 1.06
The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer (2010) 1.05
High-mobility group box 1 release and redox regulation accompany regeneration and remodeling of skeletal muscle. Antioxid Redox Signal (2011) 1.03
A chemical proteomics approach for the identification of accessible antigens expressed in human kidney cancer. Mol Cell Proteomics (2006) 1.03
Identification of new accessible tumor antigens in human colon cancer by ex vivo protein biotinylation and comparative mass spectrometry analysis. Int J Cancer (2008) 1.03
Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol (2013) 1.01
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory. Clin Cancer Res (2006) 1.01
DNA-encoded chemical libraries: advancing beyond conventional small-molecule libraries. Acc Chem Res (2014) 1.01
Synergistic therapeutic effects of a tumor targeting antibody fragment, fused to interleukin 12 and to tumor necrosis factor alpha. Cancer Res (2003) 1.01
Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res (2008) 1.01
Identification of a novel cell binding site of periostin involved in tumour growth. Eur J Cancer (2011) 1.01
Expression of Snail is associated with myofibroblast phenotype development in oral squamous cell carcinoma. Histochem Cell Biol (2009) 1.00
Expression of the E-cadherin repressors Snail, Slug and Zeb1 in urothelial carcinoma of the urinary bladder: relation to stromal fibroblast activation and invasive behaviour of carcinoma cells. Histochem Cell Biol (2012) 1.00
Genotype characterisation of Giardia duodenalis isolates from domestic and farm animals by SSU-rRNA gene sequencing. Vet Parasitol (2004) 1.00
Molecular targeting of angiogenesis. Biochim Biophys Acta (2004) 1.00
Imaging of tumor angiogenesis using 99mTc-labeled human recombinant anti-ED-B fibronectin antibody fragments. J Nucl Med (2006) 1.00
In vivo targeting of tumor-associated carbonic anhydrases using acetazolamide derivatives. Bioorg Med Chem Lett (2009) 0.99
Antibody-mediated delivery of IL-10 inhibits the progression of established collagen-induced arthritis. Arthritis Res Ther (2007) 0.99
(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of (131)I-L19-SIP radioimmunotherapy. Eur J Nucl Med Mol Imaging (2009) 0.99
Molecular imaging of atherosclerotic plaques using a human antibody against the extra-domain B of fibronectin. Circ Res (2004) 0.99